title: Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin.
abstract: BACKGROUND
  Few studies have evaluated the effects of rabeprazole on low-dose aspirin (LDA)-induced gastroduodenal injuries.
  
  
  OBJECTIVE
  To conduct a randomised, double-blind, triple-dummy, active-controlled, multicentre trial, named the PLANETARIUM study, to assess the efficacy, dose-response relationship and safety of rabeprazole for peptic ulcer recurrence in Japanese patients on long-term LDA therapy.
  
  
  METHODS
  Eligible patients had a history of endoscopically confirmed peptic ulcers and were receiving long-term LDA (81 or 100 mg/day) therapy for cardiovascular or cerebrovascular protection. Subjects were randomly segregated into three groups receiving rabeprazole 10 mg once daily (standard dose in Japan), rabeprazole 5 mg once daily, or teprenone (geranylgeranylacetone; mucosal protective agent commercially available in Japan) 50 mg three times per day as an active control. The primary endpoint was recurrence of peptic ulcers over 24 weeks.
  
  
  RESULTS
  Among 472 randomised subjects, 452 subjects (n = 151, 150, 151, respectively) constituted the full analysis set. The cumulative recurrence rates of peptic ulcers over 24 weeks in the 10- and 5-mg rabeprazole groups were 1.4% and 2.8%, respectively, both of which were significantly lower than that in the teprenone group (21.7%). The cumulative occurrence rate of bleeding ulcers over 24 weeks in the teprenone group was 4.6%, while bleeding ulcers were not observed in the 10- or 5-mg rabeprazole groups. Rabeprazole was well tolerated at both doses.
  
  
  CONCLUSIONS
  Rabeprazole prevents the recurrence of peptic ulcers with no evidence of a major dose-response effect in subjects on low-dose aspirin therapy.
authors.affiliation: Department of Internal Medicine & Gastrointestinal Endoscopy, Saga Medical School, Saga, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Iwakiri
authors.forename: K
authors.initials: K
authors.lastname: Higuchi
authors.forename: M
authors.initials: M
authors.lastname: Kato
authors.forename: M
authors.initials: M
authors.lastname: Fujishiro
authors.forename: Y
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: T
authors.initials: T
authors.lastname: Takeuchi
authors.forename: M
authors.initials: M
authors.lastname: Yamauchi
authors.forename: M
authors.initials: M
authors.lastname: Sanomura
authors.forename: H
authors.initials: H
authors.lastname: Nakagawa
authors.forename: N
authors.initials: N
authors.lastname: Sugisaki
authors.forename: Y
authors.initials: Y
authors.lastname: Okada
authors.forename: H
authors.initials: H
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Arakawa
authors.forename: K
authors.initials: K
authors.lastname: Fujimoto
mesh_terms: D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D064750:Rabeprazole / Q000627:therapeutic use*; D012008:Recurrence; D055502:Secondary Prevention; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D000897:Anti-Ulcer Agents; D005343:Fibrinolytic Agents; D064750:Rabeprazole; D001241:Aspirin